1st Quarter Results

RNS Number : 2064P
F&C Private Equity Trust PLC
24 May 2018
 

 

To: Stock Exchange

For immediate release:


24 May 2018

 

F&C Private Equity Trust plc

Quarterly results for the three months to 31 March 2018 (unaudited)
 

·      Share price total return for the three months of 6.1 per cent for the Ordinary Shares

·      Quarterly dividend of 3.57p per Ordinary Share payable on 31 July 2018

 

 

 

Manager's Review

 

Introduction

 

As at 31 March 2018, the net assets of the Company were £258.2 million, giving a Net Asset Value (NAV) per share of 349.24p, which taking into account the dividend of 3.55p per share paid on 31 January gives a decrease in total return over the quarter of 1.2%, mostly due to currency movements. At 31 March, the Company had net cash of £1.9 million. Outstanding undrawn commitments were £140.6 million with approximately £17.0 million to funds where the investment period has expired.

 

In line with the Company's policy to pay dividends on a quarterly basis, a dividend of 3.57p per share was paid on 30 April 2018 and a further dividend of 3.57p will be paid on 31 July 2018 to shareholders on the register on 6 July 2018.

 

New Investments

 

During the first quarter and immediately afterwards there were three new primary fund commitments, one secondary and three new co-investments.

 

SEK 50 million (£4.3 million) was committed to Verdane Edda, a Nordic based fund focusing on technology and technology enabled companies. £5 million was committed to Apiary Capital Partners I, a new fund specialising in the lower mid-market buyout sector of the UK. €7.0 million (£6.2 million) was committed to Volpi, a Northern Europe focused technology enabled growth fund which starts life with three investments already in place.

 

During the quarter the secondary purchase of a portfolio of private equity investments from Banco Populare de Vicenza was completed. This involved the demerger of the bank's private equity business along with the extraction, via a secondary sale to a new fund, of the portfolio of nine Italian companies. A new independent private equity management company NEM SGR has been set up and the fund is termed NEM Imprese III. The overall transaction was for €33 million and was funded by a number of BMO Global Asset Management managed funds and another private equity specialist firm.  The purchase price for the Company was €4.3 million (£3.8 million), which represents a discount to fair market value of over 30%.  The Company, along with the other investors, has undertaken to make additional capital available for new and follow-on investments on a deal by deal basis. This amounts to an additional commitment of €2.6 million (£2.3 million). Pending receipt of the first valuation post deal the investment is initially valued at cost.

 

Two new co-investments have been added during the quarter and one new co-investment since the quarter end.

 

€2.5 million (£2.2 million) has been invested in Croatia based Pet Centar, the market leader in South East Europe in large format pet stores. This deal was led by Central and Eastern Europe specialists The Rohatyn Group. The investment thesis is based on continued expansion of the chain into neighbouring territories such as Slovenia and Romania. There will be a follow-on investment of an additional €2.0 million (£1.8 million) and the Company will have just over 10% of the equity of Pet Centar. $5.0 million (£3.7 million) was also invested in US based Mexican restaurant chain Rosa Mexicana. This investment is led by Trispan, a specialist private equity firm concentrating on the hospitality sector. Very recently we have co-invested alongside Inflexion in the North Wales based builders' merchant Huws Gray. This is a minority investment in one of the leading regional builders' merchant chains in the UK. The Company's investment is £6 million.

 

The funds in the portfolio have been active in making new investments across many different geographies and sectors. Apposite Healthcare II made a follow-on investment for supported living business Swanton and invested in Ortho D, a company making medical devices for the Orthopaedic sector (£0.9 million). There was an additional follow-on for our co-investment in Swanton of £0.5 million. Also in the healthcare sector Archimed called £0.3 million for Provepharm, a company specialising in the reformulation of existing pharmaceuticals. FPE II called £0.3 million for IWSR, a provider of data to the global beverage industry.

 

Inflexion Buyout IV has completed its portfolio calling £0.5 million for two investments; Calco, a Dutch based IT recruitment and training company and Chambers, the UK based global publisher of legal rankings and directories.

 

There has been some notable activity in German speaking Europe. Bencis Buyout V called £0.7 million for Halex Holdings, a Germany based but Pan-European engineering company that makes dies for aluminium extrusion. Capvis IV called £0.5 million for process machinery business ProXES and high temperature insulation for engines business Thermamax. DBAG VII called £0.3 million for duagon, a Swiss based developer and manufacturer of components for train communication networks.

 

There was also considerable new deal activity in the Nordic element of the portfolio. Procuritas Capital VI called £0.3 million for two deals; Urkund (anti-plagiarism education software) and Byens Bilpleje (cosmetic car repairs and valeting). Summa I called £0.4 million for another two companies; Ecoline (chemical inventory management) and Milarex (seafood processing). Vaaka Partners Buyout III invested £0.8 million in Famery, the global leader in prefabricated silent working and negotiation spaces (booths) for open offices.

 

Total drawdowns for the first quarter were £11.9 million.

 

Realisations

 

There was a diverse range of exits achieved over the quarter.

 

The largest realisation of £3.1 million was August Equity Partners II's sale of healthcare company Active Assistance to a financial buyer achieving an excellent return of 4.7x cost and an IRR of 28%. Argan Capital sold fruit juice company Hortex to Mid Europa yielding £2.1 million (2.0x cost and an IRR of 9%). Procuritas Capital IV exited GRAM (Green Magnum), the ice cream machine manufacturer, returning £2.2 million (6.5x cost, IRR 44%). There was a general partner led secondary exit of almost all of our remaining position in Camden Partners III. This returned £1.8 million which was just below the latest NAV but which brought forward liquidity by more than two years. We had been in this reasonably performing fund since 2005 and this exit locks in a net return of 2.5x and an IRR of 13.5%. Not included in this exit was the sale of Camden Partners III's holding in Planet Payment, a multi-currency digital payment processing company which was acquired by Fintrax returning £0.4 million (2.9x cost, 11.2% IRR). TDR Capital II and its associated Annex Fund have successfully exited enhanced annuity company Retirement Advantage through its sale to a Canadian trade buyer. This returned a combined £0.8 million (1.6x, 13% IRR) which was creditable given that shortly post investment the government announced surprise changes to the accessibility and taxation of pensions which had a severe impact on all annuity businesses in the UK. Hutton Collins III has returned £1.0 million through the sale of 50% of its remaining portfolio in a secondary. PM & Partners II has sold Italian bakery Monviso returning £0.2 million (1.7x, IRR 10%). Chequers Capital XV sold SES-Imagotag to BOE Technology returning £0.6 million (2.3x, 10% IRR). In the US Blue Point Capital II exited Linestar Holdings, the pipeline services company, returning £0.4 million (1.3x, 5% IRR). Lastly the Aurora Fund, our own secondaries fund distributed £0.8 million during the quarter.

 

The total of realisations in the quarter was £16.1 million, including £0.4 million of income.

 

Valuation Changes

 

There were relatively few substantial changes in the first quarter when there is a relatively short period of time between published valuations. The largest influence on the valuation this quarter was currency movements with sterling having strengthened somewhat against the Euro and more noticeably against the Dollar. The net effect of this is approximately a 1% reduction in NAV. The largest movement of an individual investment was a downgrade of £1.2 million for superfoods business Nutrisure which has been put into administration by the debt provider part way through a sale process. This company has had some traction in its key markets but it has come too late to avoid loss of control by the equity syndicate.

 

Our co-investment in Sigma, the US based electrical components company, has made good progress with strong growth in revenue and new customer wins and this is uplifted by £0.5 million. Blue Point Capital II is up by £0.6 million and Inflexion 2010 is up by £0.3 million. Both funds have made good progress with their respective portfolios. Chequers Capital XV and XVI are up by a combined £0.4 million.

 

Financing

 

At the quarter end the Company is effectively ungeared. With the additional co-investments taking place after the quarter end it is anticipated that the balance sheet will become modestly geared over the next few months. The flow of realisations remains healthy so we would expect only a gradual increase in gearing. The revolving credit facility is available should it be necessary to fund investments once the existing cash balance is utilised. Discussions with the bank and other lenders will begin later this year with a view to renewing the facility.

 

Outlook

 

The private equity market internationally continues to expand both in absolute terms and as a proportion of investable assets. Current levels of fund raising and accumulated capacity to invest, often termed 'dry powder', are at or near record levels. The price of new deals across all markets is approaching all-time highs. This is something to be monitored closely and it is possible that there could be some slowdown in new deal activity from recent very active levels. The private equity sector is innately long term in its investment outlook and for mature investors there should be no pressure to invest if prices and prospective returns do not fully justify it. Our investment partners are chosen for their ability to identify and create value across a broad swathe of sectors and geographies. The lower mid-market, particularly, continues to present diligent investors with a myriad of opportunities.  We have a broadly diversified portfolio which is the result of each of these investment partners taking a few of these opportunities over a period of years. Our portfolio remains well placed to grow value for shareholders over the long term.

 

 

Hamish Mair

Investment Manager

F&C Investment Business Limited

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

F&C PRIVATE EQUITY TRUST PLC

 

Statement of Comprehensive Income for the

three months ended 31 March 2018 (unaudited)

 

 




Revenue

£'000

Capital

£'000

Total

£'000

 

Income




Losses on investments held at fair value

-

(2,881)

(2,881)

Exchange gains

-

373

373

Investment income

448

-

448

Other income

24

-

24

Total income

472

(2,508)

(2,036)





Expenditure




Investment management fee - basic fee

(159)

(476)

(635)

Other expenses

(188)

-

(188)

Total expenditure

(347)

(476)

(823)





Profit/(loss) before finance costs and taxation

125

(2,984)

(2,859)





Finance costs

(106)

(319)

(425)





Profit/(loss) before taxation

19

(3,303)

(3,284)





Taxation

(15)

15

-





Profit/(loss) for period/total comprehensive income

4

(3,288)

(3,284)





Return per Ordinary Share

0.01p

(4.45)p

(4.44)p





 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

F&C PRIVATE EQUITY TRUST PLC

 

Statement of Comprehensive Income for the

three months ended 31 March 2017 (unaudited)

 




Revenue

£'000

Capital

£'000

Total

£'000

 

Income




Gains on investments held at fair value

-

2,556

2,556

Exchange losses

-

(84)

(84)

Investment income

154

-

154

Other income

11

-

11

Total income

165

2,472

2,637





Expenditure




Investment management fee - basic fee

(158)

(475)

(633)

Investment management fee - performance fee

-

(1,390)

(1,390)

Other expenses

(191)

-

(191)

Total expenditure

(349)

(1,865)

(2,214)





(Loss)/profit before finance costs and taxation

(184)

607

423





Finance costs

(104)

(312)

(416)





(Loss)/profit before taxation

(288)

295

7





Taxation

-

-

-





(Loss)/profit for period/total comprehensive income

(288)

295

7





Return per Ordinary Share

(0.39)p

0.40p

0.01p





 

 

 

 

 



F&C PRIVATE EQUITY TRUST PLC

 

Statement of Comprehensive Income for the

year ended 31 December 2017 (audited)

 

 




Revenue

£'000

Capital

£'000

Total

£'000

 

Income




Gains on investments held at fair value

-

21,216

21,216

Exchange losses

-

(1,019)

(1,019)

Investment income

1,422

-

1,422

Other income

51

-

51

Total income

1,473

20,197

21,670





Expenditure




Investment management fee - basic fee

(641)

(1,922)

(2,563)

Investment management fee - performance fee

-

(2,037)

(2,037)

Other expenses

(830)

-

(830)

Total expenditure

(1,471)

(3,959)

(5,430)





Profit before finance costs and taxation

2

16,238

16,240





Finance costs

(428)

(1,283)

(1,711)





(Loss)/profit before taxation

(426)

14,955

14,529





Taxation

-

-

-





(Loss)/profit for year/total comprehensive income

(426)

14,955

14,529





Return per Ordinary Share

(0.58)p

20.23p

19.65p





 

 



F&C PRIVATE EQUITY TRUST PLC

 

Balance Sheet

 

 

 


As at 31 March 2018

As at 31 March 2017

As at 31 December 2017


(unaudited)

(unaudited)

(audited)


£'000

£'000

 £'000

Non-current assets




Investments at fair value through profit or loss

259,870

232,551

266,536





Current assets




Other receivables

304

34

232

Cash and cash equivalents

27,893

57,213

26,765


28,197

57,247

26,997





Current liabilities




Other payables

(3,799)

(5,092)

(3,081)

Net current assets

24,398

52,155

23,916

Total assets less current liabilities

284,268

284,706

290,452

Non-current liabilities




Interest-bearing bank loan

(26,033)

(25,176)

(26,308)

Net assets

258,235

259,530

264,144





Equity




Called-up ordinary share capital

739

739

739

Share premium account

2,527

2,527

2,527

Special distributable capital reserve

15,040

15,040

15,040

Special distributable revenue reserve

31,403

31,403

31,403

Capital redemption reserve

1,335

1,335

1,335

Capital reserve

207,187

203,974

213,100

Revenue reserve

4

4,512

-

Shareholders' funds

258,235

259,530

264,144





Net asset value per Ordinary Share

349.24p

350.99p

357.23p





 



F&C PRIVATE EQUITY TRUST PLC

           

Reconciliation of Movements in Shareholders' Funds

 

 

 

 

 

Three months ended 31 March 2018

Three months ended 31 March 2017

Year ended 31 December 2017

 

(unaudited)

(unaudited)

(audited)

 

£'000

£'000

£'000

Opening shareholders' funds

264,144

259,523

259,523

(Loss)/profit for the period/total

comprehensive income

 

(3,284)

 

7

 

14,529

Dividends paid

(2,625)

-

(9,908)

Closing shareholders' funds

258,235

259,530

264,144

 

 


Notes (unaudited)

 

1.   The unaudited quarterly results have been prepared on the basis of the accounting policies set out in the statutory accounts of the Company for the year ended 31 December 2017. 

 

2.   Investment management fee:

 

 

 

Three months ended

31 March 2018

 

 

Three months ended

 31 March 2017

 

 

Year ended

31 December 2017

 

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

 

 

 

 

 

 

 

 

 

 

Investment management       fee - basic fee

 

159

 

476

 

635

 

158

 

475

 

633

 

641

 

1,922

 

2,563

Investment management       fee - performance fee

 

-

 

-

 

-

 

-

 

1,390

 

1,390

 

-

 

2,037

 

2,037

 

 

159

 

476

 

635

 

158

 

1,865

 

2,023

 

641

 

3,959

 

4,600

 

 

 

 

 

 

 

 

 

 

 

3.   Finance costs:

 

 

 

Three months ended

31 March 2018

 

 

Three months ended

 31 March 2017

 

 

Year ended

31 December 2017

 

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

 

 

 

 

 

 

 

 

 

 

Interest payable on bank loans

106

319

425

104

312

416

428

1,283

1,711

 

 

 

 

 

 

 

 

 

 

 

4.   The return per Ordinary Share is based on a net loss on ordinary activities after taxation of £3,284,000 (31 March 2017 - profit of £7,000; 31 December 2017 - profit of £14,529,000) and on 73,941,429 (31 March 2017 - 73,941,429; 31 December 2017 - 73,941,429) shares, being the weighted average number of Ordinary Shares in issue during the period.

 

5.   The net asset value per Ordinary Share is based on net assets at the period end of £258,235,000 (31 March 2017 - £259,530,000; 31 December 2017 - £264,144,000) and on 73,941,429 (31 March 2017 - 73,941,429; 31 December 2017 - 73,941,429) shares, being the number of Ordinary Shares in issue at the period end.

 

 

6.   The financial information for the three months ended 31 March 2018, which has not been audited or reviewed by the Company's auditor, comprises non-statutory accounts within the meaning of Section 434 of the Companies Act 2006.  Statutory accounts for the year ended 31 December 2017, on which the auditor issued an unqualified report, will be lodged with the Registrar of Companies.  The quarterly report is available on the Company's website www.fcpet.co.uk.

 

 

Legal Entity Identifier: 2138009FW98WZFCGRN66

 

For more information, please contact:

 

Hamish Mair (Investment Manager)

0131 718 1184

Scott McEllen (Company Secretary)

0131 718 1137

hamish.mair@bmogam.com  / scott.mcellen@bmogam.com



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
QRFEAESLALPPEFF
UK 100

Latest directors dealings